Overview

* Cue Biopharma ( CUE ) Q3 collaboration revenue declines

* Company announces $15 mln collaboration with ImmunoScape for cell therapy development

* Operating expenses decreased due to lower clinical trial costs and compensation

Outlook

* Company did not provide specific financial guidance for future quarters in its press release

Result Drivers

* REDUCED R&D EXPENSES - Decrease in research and development expenses due to lower clinical trial costs and employee compensation

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $2.15

Collabor mln

ation

Revenue

Q3 Net -$7.45

Income mln

Q3 Basic -$0.07

EPS

Q3 -$7.60

Income mln

From

Operatio

ns

Q3 $9.74

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Cue Biopharma Inc ( CUE ) is $4.00, about 82.9% above its November 11 closing price of $0.68

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)